amine and therefore does not cross the blood-brain barrier, which prevents central side effects (anticholinergic syndrome).Ipratropium is also combined atrovent hfa canada fenoterol (trade names Combivent and atrovent hfa canada for the management of asthma.Side effects are as those for other anticholinergics.[edit] SourcesBrenner, G. M. (2000).

(IUPAC) name[8-methyl-8-(1-methylethyl)- 8-azoniabicyclo[3.2.1] oct-3-yl] 3-hydroxy-2-phenyl-propanoateIdentifiersCAS number 60205-81-4ATC code R01AX03 R03BB01PubChem 43232DrugBank APRD00537Chemical dataFormula C20H30NO3Mol. mass 389.457 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability ?Protein binding 0 to 9% in vitroMetabolism HepaticHalf life 2 hoursExcretion ?Therapeutic considerationsPregnancy cat. B(US)Legal status POM(UK)Routes InhalationIpratropium (as ipratropium bromide, trade name Atrovent) is an anticholinergic drug administered by inhalation atrovent hfa canada atrovent hfa canada treatment of obstructive lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and atrovent hfa canada secretion. It is a quaternary amine and therefore does not diffuse into the blood, which prevents atrovent hfa canada side effects. atrovent hfa canada is also combined with albuterol (salbutamol) (trade names Combivent and Duoneb) for the atrovent hfa canada of obstructive lung diseases. It acts by blocking.

Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN.